Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA)

There are currently 4500 ALXA shares in my "fund" with break-even of around 1.32 USD.
http://caps.fool.com/Blogs/fund-trades/678775.

Shamelessly following zz with a better entry point, but only because markets have a bad case of multiple personality disorder this past week.

Alexza resubmitted the Staccato Loxapine NDA today and the market yawned, passed gas, and rolled over. Well, that's fine. With everything going on most people don't want to have their money in a small speculative biotech. Important numbers to keep in mind here are 0.9 and 1.86. The former is the low of pessimism after the initial FDA rejection last October. The latter was the high point in July before the bull bubble popped. The company expects a six month class II review which would indicate a PDUFA in early February. I think the odds of second pass approval of Staccato Loxapine are about 50%, and the stock will probably sell off soon after approval. So the question is how long do you think the bear will stay out of his cage? If you're expecting more than six months, stay in cash or buy bear funds. If not, Alexza is one biotech that has a good shot at a rebound as long as the bull market comes back before the PDUFA.

Great growth potential.

Everything I read says this stock was going to double when I bought it at 1.45 a month or so ago. I still feel very good about and I think it is still undervalued.

Ascending Triangle

Great pipeline, well funded.

Upcoming catalysts that will provide a high run up before pdufa. Between the upcoming rally, the potential of az-004, and their drug delivery technology this can be a multi-bagger by the end of the year and in the long term/

Alexza is a strong company with a great pipeline!

ALXA is a stock that returns the favor in the risk you put in to it. I wouldnt be surprised if it hits 4.50 a share.

ALXA will be back to $2 in several months. I will tell you the reason later LOL

Stock gets a second chance to make their points in person to FDA. Low price right now. Much needed drug, takes agitation off of schizophrenia and Bipolor patients.

The company can address the safety issues from the recent CRL, and investors will greet the upcoming announcement of an FDA meeting date with optimism. Concerns of dilution down the road will be put aside in a run up off recent lows.

Good drug.. will get approval!!!

I think it's retraced enough here. Should be poised to make another run before October 11th. Just make sure to close your position before that date unless you want to gamble on the whims of the FDA.

Betting on approval

I am looking for at least a doulbe from here into october.

ALXA

Time to double down on Alexza